Dongqing Wang^1,*, Heying Chen¹, Yi Hu^2,*

Oncologie, Vol.24, No.3, pp. 441-449, 2022, DOI:10.32604/oncologie.2022.024898 - 19 September 2022

Abstract Immunotherapy is currently recognized as one of the most promising anticancer strategies. In the tumor microenvironment, tumor-associated macrophages are mainly M2-type macrophages with tumor-promoting effects. Therefore, the reprogramming of tumor-associated macrophages from M2 to M1 type is a potential strategy for cancer therapy. We have previously shown the anticancer effects of implantable allogeneic M1 macrophages in mice. Here, we further engineered autologous mouse bone marrow cells into M1 macrophages and then embedded them into a sodium alginate gel to prepare an implantable immunotherapeutic agent (M1@Gel). We demonstrate that M1@Gel repolarizes M2 macrophages to M1 type More >

FRANCESCO MAININI^*

BIOCELL, Vol.45, No.5, pp. 1171-1173, 2021, DOI:10.32604/biocell.2021.017399 - 12 July 2021

Abstract Adoptive cell therapy and Immune Checkpoint Blockade Inhibitors have recently revolutionized the field of oncology. However, these types of immunotherapeutic approaches have limited success in treating solid tumors. In particular, chimeric antigen receptor (CAR)-T cells efficacy is hampered by immunosuppressive signals in the tumor microenvironment (TME) and by a limited infiltration of re-infused T cells to the tumor site. The field of nanobiotechnology applied to oncology is also rapidly expanding. Nanoparticles-based delivery systems can be employed to modulate the activity of immune cells present in the TME enhancing the efficacy of CAR-T cells. Interestingly, nano-backpacks More >